Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: jj_ who wrote (2644)	1/22/2001 9:00:47 PM
From: Biomaven	Read Replies (2) \| Respond to of 52153

Haven't followed the diagnostic side of Alzheimers at all, I'm afraid. On the treatment side, it's really still too early to tell. Hundreds of players and programs. Right now all we have are some modest palliatives. NTII (FRX is the licensor) is a nano-cap play on memantine, which is the first drug I know of to have some (albeit definitely not dramatic) effect on moderate AD. ELN's vaccine produced a considerable buzz for its efficacy in rodents. Much too early to tell if it'll have any effect at all in humans, though. (Still in Phase I). This was an Athena Neuroscience program, incidentally. Rick informs me they were also the originators of Antegra, the ELN/BGEN MS drug that had news today. Here's a brief discussion of the ELN program: sciencenews.org Peter